Of note, heightened FOXM1 expression in osteosarcoma correlates with decreased response to immunotherapy [46], bolstering the possibility that inhibition of FOXM1 may be key to preventing ICB therapy resistance in our sarcoma model of MPNST. Here, FOXM1 is linked to osteosarcoma.